补充维生素D预防哮喘急性发作:个体参与者数据的系统综述与荟萃分析
BACKGROUND: A previous aggregate data meta-analysis of randomised controlled trials showed that vitamin D supplementation reduces the rate of asthma exacerbations requiring treatment with systemic corticosteroids.…
要点
- 补充维生素D可降低需全身糖皮质激素治疗的哮喘急性发作率。
- 基线25(OH)D低于25 nmol/L者急性发作率降低更显著。
- 未发现维生素D效应在各亚组间存在确定差异。
核心结论
- 补充维生素D总体降低需全身糖皮质激素治疗的哮喘急性发作率。
- 未找到该干预效应在不同患者亚组间存在差异的确切证据。
研究设计与样本
- 系统综述与个体参与者数据一步法和两步法荟萃分析。
- 检索MEDLINE、Embase、Cochrane对照试验中心注册库和Web of Science至2016年10月26日。
- 纳入8项符合条件的双盲安慰剂对照随机试验共1078例参与者,获得7项试验955例个体数据。
主要发现
- 维生素D与安慰剂在至少一次急性发作比例或首次急性发作时间上无显著差异。
关键数值与推荐
- 主要结局为需全身糖皮质激素治疗的哮喘急性发作发生率。
临床怎么用
- 对哮喘患者可考虑评估基线25(OH)D水平。
- 基线25(OH)D低于25 nmol/L的哮喘患者补充维生素D可能获益。
- 维生素D补充作为辅助策略用于减少需全身糖皮质激素治疗的急性发作。
局限性
- 仅获得7项试验955例个体数据,部分试验数据未获取。
- 基线25(OH)D低于25 nmol/L亚组样本量小(92例)。
- 亚组交互作用检验未显示统计学显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A previous aggregate data meta-analysis of randomised controlled trials showed that vitamin D supplementation reduces the rate of asthma exacerbations requiring treatment with systemic corticosteroids. Whether this effect is restricted to patients with low baseline vitamin D status is unknown. METHODS: For this systematic review and one-step and two-step meta-analysis of individual participant data, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science for double-blind, placebo-controlled, randomised controlled trials of vitamin D3 or vitamin D2 supplementation in people with asthma that reported incidence of asthma exacerbation, published between database inception and Oct 26, 2016. We analysed individual participant data requested from the principal investigator for each eligible trial, adjusting for age and sex, and clustering by study. The primary outcome was the incidence of asthma exacerbation requiring treatment with systemic corticosteroids. Mixed-effects regression models were used to obtain the pooled intervention effect with a 95% CI. Subgroup analyses were done to determine whether effects of vitamin D on risk of asthma exacerbation varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration, age, ethnic or racial origin, body-mass index, vitamin D dosing regimen, use of inhaled corticosteroids, or end-study 25(OH)D levels; post-hoc subgroup analyses were done according to sex and study duration. This study was registered with PROSPERO, number CRD42014013953. FINDINGS: Our search identified 483 unique studies, eight of which were eligible randomised controlled trials (total 1078 participants). We sought individual participant data for each and obtained it for seven studies (955 participants). Vitamin D supplementation reduced the rate of asthma exacerbation requiring treatment with systemic corticosteroids among all participants (adjusted incidence rate ratio [aIRR] 0·74, 95% CI 0·56-0·97; p=0·03; 955 participants in seven studies; high-quality evidence). There were no significant differences between vitamin D and placebo in the proportion of participants with at least one exacerbation or time to first exacerbation. Subgroup analyses of the rate of asthma exacerbations treated with systemic corticosteroids revealed that protective effects were seen in participants with baseline 25(OH)D of less than 25 nmol/L (aIRR 0·33, 0·11-0·98; p=0·046; 92 participants in three studies; moderate-quality evidence) but not in participants with higher baseline 25(OH)D levels (aIRR 0·77, 0·58-1·03; p=0·08; 764 participants in six studies; moderate-quality evidence; pinteraction=0·25). p values for interaction for all other subgroup analyses were also higher than 0·05; therefore, we did not show that the effects of this intervention are stronger in any one subgroup than in another. Six studies were assessed as being at low risk of bias, and one was assessed as being at unclear risk of bias. The two-step meta-analysis did not reveal evidence of heterogeneity of effect (I2=0·0, p=0·56). INTERPRETATION: Vitamin D supplementation reduced the rate of asthma exacerbations requiring treatment with systemic corticosteroids overall. We did not find definitive evidence that effects of this intervention differed across subgroups of patients. FUNDING: Health Technology Assessment Program, National Institute for Health Research (reference number 13/03/25).
引用
- Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med. 2017. PMID: 28986128. doi:10.1016/S2213-2600(17)30306-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。